EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Merus NV's enterprise value is $3,067.58 Mil.
Merus NV's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $54.73 Mil. Therefore, Merus NV's EV-to-Revenue for today is 56.05.
The historical rank and industry rank for Merus NV's EV-to-Revenue or its related term are showing as below:
MRUS'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.53 Med: 13.14 Max: 358.43
Current: 56.05
During the past 13 years, the highest EV-to-Revenue of Merus NV was 358.43. The lowest was 0.53. And the median was 13.14.
MRUS's EV-to-Revenue is ranked worse than 83.07% of 998
companies
in the Biotechnology industry
Industry Median: 7.38
vs MRUS: 56.05
As of today (2025-05-28), Merus NV's stock price is $50.01.
Merus NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.81. Therefore, Merus NV's PS Ratio for today is 61.89.
Merus NV EV-to-Revenue Historical Data
The historical data trend for Merus NV's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Merus NV's EV-to-Revenue
For the Biotechnology subindustry, Merus NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merus NV's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Merus NV's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Merus NV's EV-to-Revenue falls into.
Merus NV's current Enterprise Value is $3,067.58 Mil.
Merus NV's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $54.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merus NV's share price for today is $50.01.
Merus NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.81.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merus NV EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Merus NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRUS has been successfully added to your 